Neuroscience
Dementia Praecox
100%
Tardive Dyskinesia
62%
Typical Antipsychotic
60%
DNA Polymorphism
44%
Dyskinesia
43%
Habenula
30%
Antipsychotic
29%
Behavior (Neuroscience)
26%
Antidepressant
25%
L-DOPA
21%
Receptor Gene
19%
Prolactin
17%
Dopaminergic
16%
Psychoactive Drug
16%
Parkinson's Disease
14%
Atypical Antipsychotic
13%
Brain-Derived Neurotrophic Factor
13%
Risperidone
13%
Dopamine Receptor
12%
Serotonin
12%
Neurotransmitter
11%
5-HT Receptor
11%
Mood Disorder
10%
Stereotypic Movement Disorder
10%
Clozapine
9%
Depression
8%
Mental Disorder
8%
ABC Transporter Subfamily B
8%
Dopamine Receptor D2
8%
Gamma-Aminobutyric Acid
8%
Major Depressive Disorder
8%
5-HT2C Receptor
8%
Central Nervous System
7%
Serotonergic
7%
Cytochrome P450 2D6
7%
Single-Nucleotide Polymorphism
7%
Phosphatidylinositol 4 Phosphate Kinase
7%
Gamma-Hydroxybutyric Acid
7%
Amygdala
7%
Pituitary Gland
7%
Body Mass Index
7%
Oxidative Stress
7%
Benzodiazepine
7%
Adverse Effect
6%
Paliperidone
6%
Neurotransmission
6%
Dopamine Transporter
6%
Metabolic Pathway
6%
Medium Spiny Neuron
6%
GRIN2A
5%
Pharmacology, Toxicology and Pharmaceutical Science
Typical Antipsychotic
49%
Tardive Dyskinesia
45%
Antipsychotic
41%
Dyskinesia
27%
Clozapine
25%
Hyperprolactinemia
20%
Metabolic Syndrome X
20%
Psychotropic Agent
18%
Levodopa-Induced Dyskinesia
18%
Symptom
15%
Motor Dysfunction
15%
Parkinson's Disease
14%
Dopamine Receptor
14%
Disease
13%
Receptor
12%
Side Effect
11%
Antidepressant
11%
Benzodiazepine
10%
Pharmacokinetics
10%
Neurotransmitter
9%
Adverse Event
9%
Pharmacotherapy
9%
Risperidone
9%
Atypical Antipsychotics
8%
Pharmacogenetics
8%
Withdrawal Syndrome
8%
Serotonin
8%
Dopamine Receptor Stimulating Agent
8%
Prolactin
7%
Gamma-Hydroxybutyrate
7%
Polypharmacy
7%
Carbamazepine
7%
CYP2D6
7%
Prevalence
7%
Biological Marker
7%
CYP1A2
7%
Therapeutic Drug Monitoring
6%
Negative Syndrome
6%
Levodopa
6%
Huntington Chorea
5%
Placebo
5%
N Methyl Dextro Aspartic Acid Receptor
5%
Dopamine Transporter
5%
Prasterone
5%
Akathisia
5%
Dehydroepiandrosterone Sulfate
5%
Catechol
5%
Randomized Controlled Trial
5%
Methyltransferase
5%
Apolipoprotein
5%
Keyphrases
Patients with Schizophrenia
21%
Tardive Dyskinesia
20%
Antipsychotics
19%
Polymorphism
15%
Metabolic Syndrome
14%
Clozapine
12%
Antidepressants
11%
Severe Mental Illness
10%
Hyperprolactinemia
10%
Genotype
9%
Habenula
9%
Gene Polymorphism
8%
Risperidone
8%
Dopamine Receptor Gene
7%
Regional Localization
7%
Schizophrenia
6%
Dopamine D2 Receptor (DRD2)
6%
Serotonin
6%
Benzodiazepines
5%
Prolactin
5%
Vulnerability
5%
Antidepressant Treatment
5%
Levodopa-induced Dyskinesia
5%
Brain-derived Neurotrophic Factor
5%
SNP
5%
Drug-induced Hyperprolactinemia
5%
HAMD-17
5%
Atypical Antipsychotics
5%
Depressed Patients
5%
Patient Demographics
5%
Sheltered Housing
5%
Chronic Mental Illness
5%
Somatic Health
5%
Rat Brain
5%
Intervention Evaluation
5%
ABCB1 Polymorphism
5%
Dorsal Diencephalic Conduction System
5%
Forebrain
5%
Schizophrenic Patients
5%